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ABSTRAK 
 
 
Pengenalan 
‘Arteriovenous Malformation’ (AVM) merupakan sambungan yang tidak normal antara 
arteri dan vena yang memintas sistem kapilari. Walaupun ia boleh muncul di mana-mana 
lokasi, anomali vaskular ini lebih dikenali dengan kehadirannya di dalam sistem saraf pusat. 
Kehadiran AVM adalah satu per sepuluh daripada kes aneurisme otak. Kadar pendarahan 
bagi pesakit yang tidak dirawat adalah antara 2 hingga 4 peratus setahun, dengan kadar 
kematian sebanyak 5 hingga 10 peratus. 
Terdapat beberapa kaedah rawatan untuk AVM: pembedahan, embolisasi dan radiosurgeri 
stereotaktik (SRS). Pembedahan masih kekal sebagai rawatan pilihan untuk AVM gred 
rendah yang mudah dicapai. Namun, AVM yang dalam, sebagai contoh di dalam talamus 
atau akar otak, merupakan cabaran terapeutik. 
Objektif 
Mewujudkan kefahaman samada SRS atau embolisasi dapat mencapai penghapusan AVM 
secara memuaskan berbanding pembedahan, dan untuk mencari komplikasi rawatan seperti 
pendarahan dan kerosakan saraf kekal selepas rawatan, sehingga 3 tahun. 
Kaedah 
Kajian ini adalah kajian retrospektif rekod maklumat pesakit. Data yang diperoleh dari nota 
kes pesakit yang menjalani satu daripada tiga jenis rawatan untuk AVM gred Spetzler-
  xiii 
Martin I hingga III di Hospital Kuala Lumpur antara tahun 2008 dan 2011. Pesakit mendapat 
rawatan susulan dengan pengimejan sehingga 3 tahun dari tarikh rawatan. Seramai 81 
pesakit telah dimasukkan ke dalam kajian ini, di mana 30 telah menjalani pembedahan, 27 
telah mendapat rawatan embolisasi, dan 24 telah menjalani SRS. 
Keputusan 
Jumlah penghapusan AVM telah dicapai 96.2% pesakit yang menjalani pembedahan, 8.7% 
pesakit yang menjalani embolisasi dan 79.2% pesakit yang menjalani SRS. 4 pesakit yang 
menjalani pembedahan meninggal dunia (3 berkait secara lansung dengan pembedahan), dan 
4 pesakit yang mendapat embolisasi meninggal duina (3 berkait secara lansung dengan 
tatacara), manakala tiada kematian dilihat dalam kumpulan SRS. ‘Modified Rankin Scale’ 
(mRS) bagi ketiga-tiga kumpulan rawatan menunjukkan peningkatan, dengan kumpulan 
pembedahan menunjukkan peningkatan terbaik (menunjukkan skala mRS yang 
menggalakkan, daripada 70% pada bulan ketiga kepada 92.3% pada tahun ketiga). 
Kesimpulan 
Penghapusan AVM bagi setiap kumpulan rawatan adalah setara dengan analisis-meta yang 
diterbitkan pada tahun 2011, di mana penghapusan AVM berjaya dicapai dalam 96% (julat 
0%-100%) pesakit selepas pembedahan, 38% (julat 0%-75%) selepas SRS dan 13% (julat 
0%-94%) selepas embolisasi. Setiap tatacara mempunyai komplikasi yang tersendiri; namun, 
kebanyakan pesakit di ketiga-tiga kumpulan menunjukkan peningkatan atau keadaan statik 
pada skala mRS pada akhir tahun ketiga rawatan susulan. Oleh kerana kami dapat mencapai 
penghapusan AVM dengan baik menggunakan pembedahan dan SRS, adalah wajar 
sekiranya kaedah-kaedah ini diteroka dan dimajukan dengan lebih lanjut. Walau 
bagaimanapun, embolisasi masih memainkan peranan penting dalam kes-kes rumit (kawasan 
fasih/‘eloquent’ dan AVM yang besar). 
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Introduction  
Arteriovenous malformation (AVM) is an abnormal connection between arteries and veins, 
which bypasses the capillary system. Although it can appear in any location, this vascular 
anomaly is widely known due to its occurrence in the central nervous system.  
AVMs are one-tenth as common as saccular aneurysms. The rate of haemorrhage in 
untreated patients is between 2 to 4 percent per year, with a mortality rate of 5 to 10 percent. 
There are several treatment modalities for AVMs: microsurgery, endovascular embolization 
and stereotactic radiosurgery (SRS). Surgical excision remains the gold standard treatment 
  xv 
for accessible, low-grade AVM. However, resection of deep-seated AVMs, such as within 
the thalamus and the brainstem, remains a therapeutic challenge.  
Objectives  
To establish an understanding whether SRS or embolization can achieve satisfactory 
obliteration of AVM nidi for patients as opposed to microsurgical excision, and to look for 
incidence of complications such as haemorrhage and permanent neurological deficit 
following treatment, for up to 3 years.  
Methods  
This is a retrospective review of records study. The data is acquired from case notes of 
patients with intracranial AVM of Spetzler-Martin grades I to III who underwent 
monomodality treatment at Hospital Kuala Lumpur between 2008 and 2011. The patients 
were followed-up with imaging for up to 3 years from the date of treatment. A total of 81 
patients were recruited in this study, where 30 underwent microsurgical treatment, 27 
underwent embolization, and 24 underwent SRS. 
Results  
Total obliteration of AVM nidus was achieved in 96.7% of patients who underwent 
microsurgery, 8.7% of patients who underwent embolization and 79.2% of patients who 
underwent SRS. 4 patients who underwent microsurgery passed away (3 directly related to 
surgery), and 4 patients who underwent embolization passed away (3 directly related to 
procedure), whereas no mortality was seen in the SRS group. The modified Rankin Scale 
(mRS) for all three groups showed an improving trend, with the microsurgery group showing 
the best improvement (from 70% at 3 months to 92.3% at 3 years showing favourable mRS 
scores). 
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Conclusion  
The AVM nidus obliteration for each treatment group is comparable to the meta-analysis 
published in 2011, where successful AVM obliteration was achieved in 96% (range 0% - 
100%) after microsurgery, 38% (range 0% - 75%) after SRS and 13% (range 0% - 94%) 
after embolization. Each modality had its own set of complications; however, most of the 
patients in all three groups had either static or improved modified Rankin Scale (mRS) at the 
end of the 3-year follow-up. As we can achieve good AVM nidus obliteration using 
microsurgery and SRS, it will be good to explore and develop these treatment options 
further. Embolization, however, still plays a vital role in complicated cases (eloquent 
regions, large AVM). 
Keywords 
Arteriovenous malformation, brain AVM, intracranial AVM, microsurgery, endovascular 
embolization, stereotactic radiosurgery, SRS, Spetzler-Martin grades I, II and III, 
monomodality therapy for AVM, management of AVM in Malaysia 
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INTRODUCTION 
 
 
Arteriovenous malformation (AVM) is an abnormal connection between arteries and veins, 
which bypasses the capillary system. Although it can appear in any location, this vascular 
anomaly is widely known due to its occurrence in the central nervous system.  
Arteriovenous malformations (AVMs) are one-tenth as common as saccular aneurysms and 
about equally frequent in males and females (Ropper and Samuels, 2009). Bleeding or 
seizures are the main presentations. The rate of haemorrhage in untreated patients is between 
2 to 4 percent per year, with a mortality rate of 5 to 10% and a 50% risk of serious 
neurological morbidity with each haemorrhage (Reyns et al., 2007; Ropper and Samuels, 
2009). 
 
 
Figure 0-01: Diagrammatic representation of an AVM 
adapted from Neurovascular Surgical Techniques (Jabbour, 2013) 
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AVMs are commonly graded using the Spetzler-Martin Grade (SMG) system, which 
categorizes AVMs based on size (less than 3cm, 3 to 6cm, more than 6cm), eloquence of 
adjacent brain tissue (eloquent areas include the brainstem, thalamus, hypothalamus, 
cerebellar peduncles, sensorimotor cortex, language cortex, or primary visual cortex), and 
the presence of deep venous drainage (Spetzler and Martin, 1986). However, Spetzler in 
2011 proposed a 3-tiered grading system to simplify the original 5-tiered system as the 
differences in surgical results between the newly paired grades were small (A: SMG I & II, 
B: SMG III, C: SMG IV-V) (Spetzler and Ponce, 2011).  
 
 
 
 
Figure 0-02: Spetzler-Martin Grading (SMG) of intracranial AVM 
adapted from Neurovascular Surgical Techniques (Jabbour, 2013) 
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There are several treatment modalities for AVMs: microsurgery, endovascular embolization 
and stereotactic radiosurgery (SRS). Surgical excision remains the gold standard treatment 
for accessible, low-grade AVM. In a meta-analysis of 6 journals between January 2000 and 
March 2011 by van Beijnum et al, successful AVM obliteration was achieved in 96% (range 
0% - 100%) after microsurgery, 38% (range 0% - 75%) after SRS and 13% (range 0% - 
94%) after embolization (van Beijnum et al., 2011). 
However, resection of deep-seated AVMs, such as within the thalamus and the brainstem, 
remains a therapeutic challenge. In a long-term outcome study by Tomoyuki Koga et al, the 
annual haemorrhage rate before SRS was 14%, but with treatment, the obliteration rate was 
82% at 5 years after treatment, and the annual haemorrhage rate after SRS dropped to 0.36% 
(Koga et al., 2010). 
This is a retrospective review of records study to ascertain the efficacy of microsurgery, 
embolization and SRS for patients with AVMs of SMG I, II and III in Hospital Kuala 
Lumpur between 2008 and 2011, and in determining their outcome up to a period of 3 years 
post treatment. 
  4 
CHAPTER 1: INTRACRANIAL ARTERIOVENOUS 
MALFORMATIONS 
 
 
1.01: PATHOLOGY 
Arteriovenous malformations (AVMs) are lesions defined by the presence of arteriovenous 
shunting through a nidus of coiled and tortuous vascular connections between feeding 
arteries and draining veins. Seen under the microscope, cells within the nest show chronic 
reactive changes and are thought to be non-functioning. The vessels retain the characteristic 
feeding artery and draining vein components, though without capillaries in between, thus 
creating a direct arteriovenous shunting. Arterial and venous elements show luminal 
hypertrophy. The elastic lamina of the arterial intimal layer is mostly intact, but it might 
show some degradation. The arterialized veins can be recognized by their size and by the 
absence of elastic staining. If bleeding has occurred, the surrounding parenchyma will show 
gliosis and hemosiderin staining. 
 
1.02: EMBRYOGENESIS 
Yasargil postulated in 1987 that AVMs might be a “proliferative capillaropathy” instead of a 
simple structural connection between arterial and venous systems (Fleetwood and Steinberg, 
2002). This suggestion is supported by several case reports and two theories. 
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Most theories state that AVMs are congenital lesions, attributed with either a persistent 
primitive arteriovenous connection, or a development of this connection after its initial 
closure. However, in 1996, Mullan and colleagues showed that AVMs are impossible to 
identify in utero or with perinatal ultrasound, which suggests that they are either too small to 
be detected in those early stages, or that they develop after birth (Mullan et al., 1996).  They 
speculated that the origins of AVMs might be related to sequential formation and absorption 
of surface veins that occur in the 40- to 80-mm length interval of human embryonic 
development. However, persistent AVM growth is possible even after birth. In 1997, 
Lasjaunias speculated that AVMs are the result of biological dysfunction of the remodelling 
process at the junction of capillaries and veins from genetically-controlled maintenance and 
homeostasis, rather than as congenital structural anomalies (Lasjaunias, 1997). 
 
1.03: NATURAL HISTORY AND CLINICAL PRESENTATION 
53% of patients with AVMs will present with haemorrhage. In a meta-analysis of nine 
natural history studies with 3923 patients, the overall annual haemorrhage rate was 3.0%. 
For patients with unruptured AVMs, the annual rate of haemorrhage was 2.2%, whereas for 
patients with ruptured AVMs, the rate was 4.5%. Deep-seated AVMs, AVMs with previous 
haemorrhage, AVMs that have exclusive deep venous drainage, as well as AVMs with 
associated aneurysms were also found to have higher annual haemorrhage rates compared to 
their counterparts (Gross and Du, 2013).  The risk of haemorrhage goes up to 6.0-6.9% 
within the first year after a rupture, but returns to the baseline annual risk of haemorrhage 
thereafter. Morbidity after an AVM rupture has been recorded to be as high as 53.0-81.0%, 
and mortality after the initial rupture is 10.0-16.6% (Fleetwood and Steinberg, 2002). 
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Table 1-01: Natural history studies for arteriovenous malformations 
Author (year) Study Type 
Number 
of 
Patients 
Average 
Years of 
F/U 
Annual Haemorrhage Rate 
Graf et al. 
(1983) 
Retrospective 164 4.8 2-3%; 6% at first year, then 
2%/year 
Crawford et al. 
(1986) 
Retrospective 217 10.4 2%; 36% cumulative risk 
with previous haemorrhage 
& 17% without haemorrhage 
at 10 years 
Brown (1988) Retrospective 168 8.2 2.2% 
Ondra et al. 
(1990) 
Retrospective 160 23.7 4% overall; 3.9% with 
haemorrhage; 4.3% with 
seizures 
Mast et al. 
(1997) 
Prospective 139 1.0 2.2% without haemorrhage; 
17.8% with haemorrhage 
Halim et al. 
(2004) 
Retrospective 790 4.0 7% for the first year, then 
3%/year 
Gross & Du 
(2013) 
Meta-analysis 3923 18,423 
patient-
years 
3% overall; 2.2% without 
haemorrhage; 4.5% with 
haemorrhage;  
 
The size of the nidus can influence the risk of haemorrhage, as the intranidal pressure of 
small AVMs is higher to that of larger AVMs. Typically, the haemorrhage is 
intraparenchymal; however, intraventricular and subarachnoid bleeding may also occur. 
Vasospasm rarely follows an AVM rupture as opposed to an aneurysmal rupture. 
The second most common presentation is seizures, which occur in 10-30% of patients 
(Jabbour, 2013). Others include headaches and focal neurological deficits, the latter 
presumably from direct mass effect on the eloquent brain or relative hypoperfusion from the 
vascular steal phenomenon.  
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7% of patients with AVMs have aneurysms, and 75% of these aneurysms are found on major 
feeding arteries, likely from the increased flow. These arterial aneurysms can be classified 
into 5 types, as shown in Table 1-02. Aneurysms may also be found within the nidus or on 
draining veins (Greenberg, 2010). 
 
Table 1-02: Categories of aneurysms associated with AVMs 
Type Aneurysm Location 
I Proximal on ipsilateral major artery feeding the AVM 
IA Proximal on major artery related to but contralateral to AVM 
II Distal on superficial feeding artery 
III Proximal or distal on deep feeding artery 
IV On artery related to AVM 
 
1.04: EPIDEMIOLOGY AND DEMOGRAPHICS 
From the Cooperative Study of Intracranial Aneurysms and Subarachnoid Haemorrhage and 
early autopsy series, the prevalence of intracranial AVMs are estimated at 140-500 per 
100,000 people, affecting 0.14-0.50% of the population (McCormick, 1966; Perret and 
Nishioka, 1966). Hofmeister et al, in a review of 1289 patients, observed a mean age at 
diagnosis of 31.2 years, with 45% of the patients being female (Hofmeister et al., 2000). 
However, intracranial AVMs can present in patients of any age, and the distribution between 
sexes is equal (Choi and Mohr, 2005). 
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1.05: DIAGNOSTIC EVALUATION 
For patients presenting with neurologic sequelae of AVMs, computed tomography (CT) scan 
is the initial screening tool, which will show the location of the lesion, the acute 
haemorrhage, and the presence of intraventricular haemorrhage and/or hydrocephalus. On a 
plain CT, unruptured AVMs may appear as irregular hyperdense areas with or without 
calcifications. Contrast-enhanced CTs may show the nidus and feeding vessels or dilated 
draining veins (Geibprasert et al., 2010). 
Magnetic resonance imaging (MRI) can delineate details of the architecture of the AVM 
where features like the anatomic relationships of the feeding arteries, nidus and draining 
veins, and the topography between the AVM and adjacent brain can be appreciated. AVMs 
can bee seen as sponge-like structures with patchy flow voids on T2-weighted images 
(T2WI). However, magnetic resonance angiography (MRA) cannot replace conventional 
cerebral angiography, and in ruptured AVMs, the hematoma may obscure the AVMs on an 
MRI (Morris et al., 2009). 
Cerebral angiogram is an obligatory step in the preoperative evaluation of patients with 
AVMs, and is a gold standard for these lesions (Farhat, 2011). Not only can it localize the 
nidus, feeding arteries and draining veins, it can also detect associated aneurysms and other 
AVM-related factors associated with a high risk of haemorrhage. 
In cases where the AVM is close to or on the eloquent areas of the brain (sensory, motor, 
language and visual cortex, hypothalamus and thalamus, internal capsule, brainstem), the use 
of positron emission tomography or functional MRI (fMRI) may be useful in determining 
the appropriate treatment modalities. 
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Figure 1-01A: Axial and coronal views of T1WI (above) and axial view of T2WI of MRI 
showing vascular flow voids at the posterior left temporal region. A dilated draining vein 
that connects to the left sigmoid sinus can easily be seen on T2WI. 
 
Figure 1-01B: MRA showing the same left temporal AVM in 3-dimensional views. 
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Figure 1-02: left vertebral artery run of cerebral angiogram shows a small left temporal 
AVM, whose feeders come from branches of the distal posterior cerebral artery (PCA) 
and posterior communicating artery (PCA), and whose draining veins 
flow superficially (SMG I). 
 
1.06: CLASSIFICATION 
In 1977, Luessenhop and Gennarelli proposed a classification system based on the number of 
arterial supply of AVMs. Grades I through IV were given corresponding to the number of 
feeding arteries from one vascular territory; no additional grade was assigned if the number 
exceeded 4, and the lesion was deemed inoperable. It did not take into consideration the 
draining veins or whether the lesions were located in the eloquent areas of the brain 
(Luessenhop and Spence, 1960; Quinones-Hinojosa, 2012). Luessenhop and Rosa published 
a grading scale in 1984 based on the size of the AVM; however, it was not practical for 
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surgical purposes, as it also did not consider draining veins and association with eloquent 
areas of the brain (Stieg and Batjer, 2006). 
In 1986, Shi and Chen a classification based on the size, location, arterial supply and 
drainage of an AVM. AVMs were graded according to these parameters (Stieg and Batjer, 
2006): 
1. Size—largest diameter of the nidus on angiogram (excluding distal parts of the 
draining veins). Grades 1 to 4 are given based on size of less than 2.5cm, 2.5 to 5cm, 
5 to 7.5cm, and greater than 7.5cm, respectively. 
2. Location and depth—superficial versus deep, “functional” versus “non-functional”, 
corpus callosum, brain stem, diencephalon. Grades 1 to 4 are assigned on the basis 
of increasing anatomic complexity and “functionality”. 
3. Arterial supply—grade 1 for single superficial feeder (MCA/ACA), grade 2 for 
multiple superficial feeders (MCA/ACA), grade 3 for branches of PCA or deep 
MCA/ACA branches or vertebral artery, and grade 4 for main branches of all three 
territories or vertebrobasilar system. 
4. Venous drainage—single superficial (grade 1), multiple superficial (grade 2), deep 
(grade 3), deep with aneurysmal venous dilatation (grade 4). 
The final grade is determined by a simple algorithm and matched with the highest grade(s) if 
at least two criteria are in that grade. Grade IV patients are not subjected to surgery. 
However, it is a complex classification and difficult to remember. 
Spetzler and Martin proposed their classification in the same issue of the Journal of 
Neurosurgery as Shi and Chen in 1986, based on the size of the nidus, the pattern of venous 
drainage, and the association with eloquent areas of the brain. This classification turned out 
to be the most practical one due to its simplicity and the low inter-observer variability, thus 
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became widely accepted, and is still applicable today (Spetzler and Martin, 1986; Quinones-
Hinojosa, 2012). 
 
Table 1-03: Spetzler-Martin Scale for Grading Arteriovenous Malformations 
Variable Points 
Size 
     <3cm 
     3-6cm 
     >6cm 
 
1 
2 
3 
Venous drainage 
     Superficial 
     Deep 
 
0 
1 
Brain region 
     Non-eloquent 
     Eloquent 
 
0 
1 
 
The scale consists of 5 grades with 12 possible combinations, as shown in Figure 0-02. 
Lesions in which surgical resection would invariably lead to death or major deficit, such as 
very large AVMs within eloquent areas such as the thalamus or brain stem, a separate grade 
(grade 6, or inoperable) is given. 
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Several other authors have proposed different classifications for AVMs, including Pertuiset 
et al. in 1991, Höllerhage et al. in 1992, and Malik et al. in 1994. To note, Malik et al. 
proposed a system based for the first time on AVM volume, location, and nature of arterial 
feeders (Malik et al., 1994; Stieg and Batjer, 2006). 
1. Volume is approximated by using the formula of (length x width x height)/2. 
Volumes are then divided into six grades. 
2. Location is divided into 4 categories following the scheme of Shi and Chen. 
• Cortical simple: non-eloquent cortex (including visual cortex); 
• Cortical functional: sensorimotor/speech; 
• Deep non-vital: insula, basal ganglia, anterior limb of internal capsule, 
corpus callosum, medial temporal lobe, intra- and periventricular, and 
cerebellar nuclei; 
• Deep vital: genu and posterior limb of internal capsule, thalamus and 
hypothalamus, and brain stem. 
3. Arterial feeders are divided into superficial or deep, including lenticulostriate 
arteries, thalamo-perforator arteries, choroidal arteries, and brain stem perforators. 
The final grade is determined by characterizing the type of location followed by size. If any 
of the arterial feeders are deep, an “A” is attached.  
With the application of the Spetzler-Martin grading (SMG) system, it became clear that 
AVMs of SMG III presented different difficulties in treatment and prognosis. Several 
authors have proposed modifications to this classification. de Oliveira et al. further divides 
SMG III into IIIA (large) and IIIB (small, in eloquent areas) (de Oliveira et al., 1998). 
However, SMG classification is still the most commonly used, and treatment criteria are 
mostly based on it. Although the classification proposed by Malik et al. has not yet been 
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clinically tested, it introduces a valuable addition by implementing volume instead of the 
more imprecise measurement of maximum diameter. 
 
1.07: TREATMENT 
When dealing with AVMs, Drake proposed five options for neurosurgeons (Drake, 1979): 
• Expectant behaviour; 
• Surgery; 
• Endovascular therapy; 
• Radiotherapy (radiosurgery); 
• Combination of the above options. 
Although it was published in 1979, the options for treatments are still applicable today. Once 
a complete resection of an AVM is done, with no angiographic evidence of remaining 
lesions, the patient can be deemed cured. Nevertheless, AVM relapses have been reported 
(Quinones-Hinojosa, 2012). Advances in neuroimaging and in neuro-anaesthesia with brain 
protection allow for complex surgeries to be safer and less harmful. 
Microsurgery is reported to have a low risk of complications for SMG I and II, with 
immediate cure. However, surgery is invasive. SRS can be effective for lesions smaller than 
3.5 cm, but complete obliteration requires between 1 and 3 years after treatment, and may 
not always be obtained. Embolization is used to obliterate small malformations or to make 
larger malformations amendable for microsurgery or SRS. AVMs of SMG IV or V generally 
require multimodality treatment (van Beijnum et al., 2011). 
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Patient factors must also be considered in decision-making. Age, presentation, medical 
comorbidities, as well as functional status and social factors have to be addressed. Elderly 
patients with multiple comorbidities and an incidental finding of an unruptured AVM may 
be treated conservatively, but young patients should be worked up for treatment in view of 
the cumulative risk of haemorrhage. Assuming an annual haemorrhage rate of 2-4%, with an 
average life expectancy of 70 years, the cumulative risk (in percentage) of an AVM to 
rupture can be estimated using this formula (Brown, 2000; Farhat, 2011): 
Lifetime risk (%) = 105 – patient’s age in years. 
Patients with a ruptured AVM should be stabilized first and be allowed to recover 
neurological function before the AVM is tackled. In cases where the hematoma is causing a 
mass effect, the clots may be evacuated first, before revisiting the lesion later in a controlled, 
elective environment. 
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CHAPTER 2: LITERATURE REVIEW 
 
 
2.01: A 3-TIER CLASSIFICATION OF CEREBRAL ARTERIOVENOUS 
MALFORMATIONS (SPETZLER AND PONCE, 2011) 
As mentioned in the previous chapter, Spetzler and Martin had proposed a grading system 
for intracranial AVMs in 1986 based on the size of the nidus, the location of the AVM 
whether it is in an eloquent area of the brain, and the presence of deep venous drainage. The 
Spetzler-Martin grading (SMG) classification has since been widely accepted and applied. 
Since the management of AVMs at the Barrow Neurological Institute practices a treatment 
paradigm where SMG I and II are managed in a similar fashion, as are SMG IV and V, the 
authors have proposed a system consisting of 3 classes (please also refer to Figure 0-02): 
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Table 2-01: Proposed 3-tier classification of cerebral AVMs with treatment paradigm, 
adapted from “A 3-tier Classification of Cerebral Arteriovenous Malformations” 
Class 
Spetzler-Martin 
Grade (SMG) 
Management 
A I & II resection 
B III multimodality treatment 
C IV & V no treatment* 
* Exceptions for treatment of Class C AVMs include recurrent haemorrhages, 
progressive neurological deficits, steal-related symptoms, and AVM-related 
aneurysms. 
7 surgical series were considered in this study, and the authors found no significant 
difference between the outcomes of SMG I and II or SMG IV and V AVMs. The authors 
recommended microsurgical resection as the management of Class A AVMs, as a study by 
Davidson and Morgan reported a 0.7% risk of adverse surgery-related outcomes for this 
group of patients. 
For Class B AVMs, the management is more individualized and tailored to suit the patient’s 
situation, although it typically requires a multimodality approach. de Oliveira et al, when 
subdividing SMG III into IIIA (large) and IIIB (small, in eloquent areas), recommended 
embolization followed by microsurgery for IIIA, and radiosurgery alone for IIIB (de Oliveira 
et al., 1998).  
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Medical management is recommended for Class C AVMs except for cases with repeated 
haemorrhages or progressive neurological deficits in view of the high reported rates of 
morbidity associated with surgery and possible risk of haemorrhage associated with radiation 
or partial embolization. 
 
2.02: MEDICAL MANAGEMENT WITH OR WITHOUT 
INTERVENTIONAL THERAPY FOR UNRUPTURED BRAIN 
ARTERIOVENOUS MALFORMATIONS (ARUBA): A MULTICENTER, 
NON-BLINDED, RANDOMIZED TRIAL (MOHR ET AL., 2014) 
This study was aimed to compare the risk of death and symptomatic stroke in patients with 
an unruptured brain arteriovenous malformation who were either treated medically alone 
(experimental study group), or medical management with interventional therapy (standard 
treatment). It recruited patients at 39 clinical sites in nine countries, starting from April 4, 
2007. 
Randomization was stopped on April 15, 2013 due to the superiority of the medical 
management group (log-rank Z statistic of 4.10, above the pre-specified boundary value of 
2.87). At that point, outcome data for 223 patients were available, where 114 patients 
(51.1%) had been assigned to interventional therapy and 109 patients (48.9%) to medical 
management. Patients with SMG I-IV were included in this study, and most (62%) had 
scores of II or less. 
35 out of 114 patients from the interventional study (30.7%) reached the study’s endpoint of 
death or stroke (25 patients developed haemorrhagic stroke, 9 patients developed ischemic 
stroke, and 3 patients died). As for the medical management group, 11 out of 109 patients 
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(10.1%) reached the endpoint (6 patients developed haemorrhagic stroke, 3 patients 
developed ischemic stroke, and 2 patients died). The hazard ratio (instantaneous risk) was 
significantly less in the medical management group (HR 0.27, 95%CI 0.14-0.54) as 
compared with the interventional therapy group (p <0.0001). 
  
2.03: TREATMENT OF BRAIN ARTERIOVENOUS 
MALFORMATIONS: A SYSTEMATIC REVIEW AND META-
ANALYSIS (VAN BEIJNUM ET AL., 2011) 
In 2011, van Beijnum et al. published a meta-analysis on 137 observational studies with a 
total of 13,698 patients and 46,314 patient-years of follow-up. This study measured the 
outcomes following treatment of arteriovenous malformations (AVMs) with microsurgery, 
embolization, stereotactic radiosurgery (SRS), or a combination of treatment modalities. The 
study was aimed to assess the rates of successful obliteration of brain AVMs, rates of case 
fatality, long-term risk of haemorrhage and complications following interventional 
treatment.  
In this study, the primary outcome was all-cause case fatality during treatment and follow-
up. The secondary outcome was intracranial haemorrhage beyond 30 days of treatment, as 
haemorrhage within 30 days was considered a complication of treatment. The tertiary 
outcomes were treatment complications and successful obliteration of the AVMs. 
From the 137 articles reporting on 142 cohorts, 41 cohorts (29%) reported on microsurgery, 
14 (10%) reported on embolization, 69 (48%) reported on SRS, 7 (5%) reported on 
fractionated radiotherapy, while 11 (8%) described either multimodality treatment, various 
treatments within 1 article, or another treatment such as intraoperative embolization.  
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Table 2-02: Primary, Secondary and Tertiary Outcome measures 
Adapted from “Treatment of Brain Arteriovenous Malformations: A Systematic 
Review and Meta-analysis” (van Beijnum et al., 2011) 
 
No. (%) of 
Cohort [Study 
Sample Size] 
Estimate (95% 
CI) per 100 
Person-Years 
Median (Range), 
% 
Overall 
Case fatality 
Haemorrhage 
Follow-up, person-years 
Follow-up, mo 
 
142 [13,698] 
142 [13,698] 
142 [13,698] 
124 [11,287] 
 
0.68 (0.61-0.76) 
1.4 (1.3-1.5) 
 
1.5 (0-29) 
3.6 (0-46) 
157 (3.5-3900) 
30 (2.0-123) 
Microsurgery 
Case fatality 
Haemorrhage 
Complications, % 
     Acute 
     Severe 
Obliteration, % 
Follow-up, person-year 
Follow-up, mo 
 
41 [2549] 
41 [2549] 
 
33 (80) [1655] 
24 (30) [1252] 
34 (85) [1837] 
41 [2549] 
35 (85) [2309] 
 
1.1 (0.87-1.3) 
0.18 (0.10-0.30) 
 
 
 
96 (0-100) 
72 (3.5-2063) 
17 (2.0-98) 
 
0.67 (0-13) 
0 (0-11) 
 
29 (1.5-54) 
7.4 (0-40) 
SRS 
Case fatality 
Haemorrhage 
Complications, % 
     Acute 
     Acute severe 
     Late 
     Late severe 
Obliteration, % 
Follow-up, person-year 
Follow-up, mo 
 
69 [9436] 
69 [9436] 
 
33 (48) [3290] 
32 (46) [2558] 
63 (91) [6914] 
35 (51) [2862] 
57 (83) [7996] 
69 [9436] 
68 (99) [7501] 
 
0.50 (0.43-0.58) 
1.7 (1.5-1.8) 
 
1.1 (0-12) 
5.8 (0-21) 
 
0 (0-16) 
0 (0-4.8) 
13 (0-63) 
5.1 (0-21) 
38 (0-75) 
202 (21-3900) 
35 (8.0-94) 
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No. (%) of 
Cohort [Study 
Sample Size] 
Estimate (95% 
CI) per 100 
Person-Years 
Median (Range), 
% 
Embolization 
Case fatality 
Haemorrhage 
Complications, % 
     Acute 
     Severe 
Obliteration, % 
Follow-up, person-year 
Follow-up, mo 
 
14 [1019] 
14 {1019] 
 
18 (100) [1201] 
16 (89) [818] 
13 (72) [786] 
14 [1019] 
11 (79) [926] 
 
0.96 (0.67-1.4) 
1.7 (1.3-2.3) 
 
2.5 (0-12) 
1.9 (0-14) 
 
25 (7.6-55) 
6.6 (0-28) 
13 (0-94) 
137 (7.5-931) 
27 (5.3-78) 
 
In this study, obliteration was achieved in 96% (range, 0%-100%) of patients who underwent 
microsurgery, in 38% (range, 0%-75%) after SRS, and in 13% (range, 0%-94%) after 
embolization. Complications leading to death or permanent neurological deficits occurred in 
a median of 7.4% (range, 0%-40%) after microsurgery, 5.1% (range, 0%-21%) after SRS, 
and 6.6% (range, 0%-28%) after embolization. 
It was also noted that complete obliteration was obtained in a high proportion of patients 
who underwent microsurgery, whereas embolization as a monotherapy was achieved in a 
minority of patients. SRS was reported to be associated with a low case fatality, but at the 
expense of a low obliteration rate. The authors commented that the 2-year obliteration rate 
after SRS is probably in the range of 40% as opposed to the commonly cited 80%. 
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2.04: WHEN TO TREAT AN AVM 
When an AVM has bled, it has to be treated. The same goes for AVM-related epilepsy 
refractory to medical treatment. Unruptured AVMs that show no clinical manifestation but 
with imaging evidence of intranidal aneurysms, stenosis of the feeding arteries or significant 
venous stenosis should also be treated. The following guideline can be used based on the 
SMG scale (Quinones-Hinojosa, 2012). 
Grades I and II AVMs 
Grade I AVM should always be treated. As they do not, in principle, pose any difficulty for 
the surgeon, microsurgery without prior endovascular treatment is the indicated and curative 
procedure. For unruptured SMG I AVMs, SRS is another option; however, the AVM may 
bleed during the time it takes to disappear. Endovascular option would be the last for this 
group, for even though there is angiographic evidence of lesion disappearance, non-visible 
pedicles may exist that may cause the nidus to reappear. 
SMG I AVM 
1. Surgery 
2. Radiosurgery 
3. Endovascular therapy 
4. Do nothing 
As with SMG I AVMs, SMG II should be treated, as the natural risks are higher than those 
of treatment complications. Microsurgery is the first-line treatment for SMG II. 
Endovascular therapy may be of help prior to surgery. It is possible to achieve angiographic 
total obliteration of AVM via endovascular therapy alone, but it is also likely that non-
visible pedicles may still exist. Radiosurgery as a monotherapy is not indicated. It has been 
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proven that the area to be radiated does not include the entire nidus, and that areas treated 
endovascularly may not be included, thus leading to lesion reproduction. 
SMG II AVM 
1. Surgery 
2. Endovascular therapy + surgery 
3. Endovascular therapy 
4. Radiosurgery 
5. Surgery + radiosurgery 
Grade III AVM 
SMG III AVMs must always be treated, but management may be problematic in view of the 
variants that appear in this group (S1E1D1, S2E1D0, S2E0D1, S3E0D0). Endovascular 
therapy becomes essential in these situations by progressively occluding the afferent vessels 
without causing a sudden redistribution of flow prior to surgery. A time of no less than 4 to 5 
days should be given before proceeding with surgery. Direct microsurgery can be done, but 
pre-embolized SMG III AVMs will bleed less. Endovascular therapy with SRS and SRS 
alone are also valid treatment options. 
SMG III AVM 
1. Endovascular therapy + surgery 
2. Surgery 
3. Endovascular therapy + surgery + SRS 
4. Endovascular therapy + radiosurgery 
5. SRS 
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Grade IV AVMs 
Unruptured SMG IV AVMs that do not have intranidal aneurysms should be controlled 
clinically and with imaging evaluation. The mortality and morbidity rates of treatment are 
higher than that of the AVM’s natural history. However, if there is presence of haemorrhage, 
these lesions should be treated in view of the higher risk of rebleed. Treatment should always 
be a combination of techniques, starting from endovascular therapy, which may take at least 
2 sessions. Once the endovascular treatment has been completed, and enough time has 
elapsed, surgery is the next step. If post-surgery angiography shows any remnant, the 
treatment is completed with radiosurgery. 
SMG IV AVM 
1. Do nothing 
2. Endovascular therapy + surgery 
3. Endovascular therapy + surgery + SRS 
4. Endovascular therapy + SRS (palliative) 
5. Endovascular therapy (palliative) 
Grade V AVMs 
In principle, SMG V AVMs are not treated. Cure is possible, but the complication rates are 
high. If they cause recurrent bleedings, treatment should be tried, though it will always be 
palliative, with endovascular therapy as the mainstay of the management plan. 
SMG V AVM 
1. Do nothing 
2. Endovascular therapy + SRS 
3. Endovascular therapy 
